CoolTech develops transnasal cooling technology for non-invasive fever control and neuroprotection.
CoolTech develops transnasal cooling technology for non-invasive fever control and neuroprotection. Its CoolStat device is small, lightweight, and portable, able to move throughout the hospital with the patient. The device generates a source of filtered air that is delivered to the patient via a single-use air tubing set.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 18, 2022 | Seed | $200K | 1 | TEDCO | — | Detail |